Skip to content
Search

Latest Stories

Former promoters of Ranbaxy arrested in India

TYCOON brothers Shivinder and Malvinder Singh appeared in court Friday (11) accused of siphoning off hundreds of millions of dollars in the latest episode of a crumbling business dynasty.

The former owners of the Ranbaxy generic drugs giant, who are said to have lost a fortune worth billions over the past decade, are in court over $337 million diverted from the Religare financial group which they built up.


The brothers, also wrangling with each other over the lost money, were detained separately late Thursday and charged along with three other top executives from the group.

The court gave police four days to question the brothers, who have launched a counter action calling for the investigation to be declared invalid.

Police said in a statement that the suspects had put Religare "in poor financial condition by way of disbursing the loans to companies having no financial standing."

The suspects "systematically siphoned off and diverted money ... in a clandestine manner for their own benefit," the statement added.

The detention could speed the fall of the Singhs, whose grandfather and father built up Ranbaxy to become India's largest pharmaceutical group.

Japan's Daiichi Sankyo bought out Ranbaxy in 2008 in a deal valued at $4.6 billion.

Some of that went to repay loans and debt but the Singh brothers are said to have lost two billion dollars in bad deals and decisions as they built up Religare and the Fortis hospital and health group.

But much focus has been put on more than $350m that media reports said the Singhs' group loaned to companies and interests of Gurinder Singh Dhillon, the guru at the head of a sect that claims four million members worldwide.

The brothers have acknowledged that they had financial dealings with Dhillon and his Radha Soami Satsang Beas group. But they deny that Dhillon was the cause of their financial meltdown.

Dhillon, a relative of the Singhs' mother, has not commented on the brothers' troubles.

The Singhs were forced out of Religare and Fortis in 2018 and said in a statement to the Business Today magazine one year ago that they had sold virtually all their shares and assets to pay off debts.

Huge claims remain however and many of their remaining assets are under court control.

Daiichi Sankyo won a $500m compensation order against the brothers at an international tribunal in Singapore in 2016 after claiming that they had withheld key information during the sale of Ranbaxy.

India ranks third in the world for the number of family owned conglomerates, behind China and the United States, according to a recent Credit Suisse report.

Conflicts are common within the families. But Business Today said: "Such decimation of a flourishing and diversified empire within a decade is unprecedented in India's corporate history."

(AFP)

More For You

Jaguar Land Rover

Vehicle production came to a complete halt on September (1) with JLR unable to resume global operations until five weeks later

Getty Images

Jaguar Land Rover production plunges 43 per cent following devastating cyber attack

Highlights

  • JLR produced only 59,200 cars in final quarter of 2025 compared to 104,400 previous year, down 43 per cent due to cyber attack fallout.
  • Operations halted globally for five weeks from September after August breach described as Britain's most expensive cyber attack.
  • Retail sales plummeted 25 per cent to 79,600 vehicles; company preparing to launch £100,000+ electric Jaguar saloon later this year.

Car production at Jaguar Land Rover plummeted by 45,000 vehicles in the final quarter of 2025 as the British automotive giant struggled with the aftermath of what experts have described as the most expensive cyber attack in British history.

The company revealed total output in the three months to December was down 43 per cent compared to last year, despite restarting factory lines in the second week of October. JLR produced just 59,200 cars in the final quarter of 2025, compared to 104,400 the previous year.

Keep ReadingShow less